Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | IL16 |
| Gene Name: | IL16 |
| Protein Full Name: | Pro-interleukin-16 |
| Alias: | HsT19289; IL-16; Interleukin 16; LCF; Lymphocyte chemoattractant factor; Neural interleukin-16; PrIL-16 |
| Mass (Da): | 141752 |
| Number AA: | 1332 |
| UniProt ID: | Q14005 |
| Locus ID: | 3603 |
| COSMIC ID: | IL16 |
| Gene location on chromosome: | 15q26.3 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 1.11 |
| Normal role description: | Stimulates migration in CD4+ lymphocytes, monocytes, and eosinophils. Is a ligand for CD4 and induces T-lymphocyte expression of interleukin 2 receptor. Isoform 1 and 3 may act as scaffolding proteins. Isoform 3 blocks cell cycle progression in resting T-cells. |